EG 427
Created in 2019
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
2,066Activities
Technologies
Entity types
Location
29 Rue du Faubourg Saint-Jacques, 75014 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 26
Engaged catalyst
12
0 0Added in Motherbase
1 year, 9 months ago
Value proposition
Pinpoint Gene Therapy
At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform called HERMES, delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology.
Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.
Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.
Gene therapy, peripheral nervous system disorders, neurogenic bladder, HSV-1 vector platform, urinary bladder dysfunction, Herpes type 1 gene therapy platform, and treatment of nervous system disordersOriginal language
Pinpoint Gene Therapy
At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform called HERMES, delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology.
Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.
Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.
PINPOINT DNA MEDICINES FOR CHRONIC DISEASES
https://www.eg427.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Gouvernement | Other 11 Apr 2025 | | |
 Ministère chargé de l'Enseignement supérieur et de la Recherche Government Administration | Ministère chargé de l'Enseignement supérieur et de la Recherche Government Administration | Other 11 Apr 2025 | | |
 Ministry of Economy Government Administration | Ministry of Economy Government Administration | Other 11 Apr 2025 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 11 Apr 2025 | | |
 Région Ile de France National and local authorities, Government Administration | Région Ile de France National and local authorities, Government Administration | Other 11 Apr 2025 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 11 Apr 2025 | | |
 | Toulouse Tech Transfer | Other 8 Mar 2025 | | |
 Avolta Finance, Investment Banking | Avolta Finance, Investment Banking | Other 22 Feb 2025 | | |
 | Réseau SATT | Other 7 Mar 2025 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 4 Mar 2025 | | |